Remission: A realistic goal in rheumatoid arthritis?

International Journal of Clinical Rheumatology

Volumn 6, Issue 6, 2011, Pages 643-647

  Sokka, Tuulikki ^a   Hannonen, Pekka ^a   Mäkinen, Heidi ^b  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

outcomes; remission; rheumatoid arthritis

Indexed keywords

BIOLOGICAL PRODUCT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TRIAMCINOLONE HEXACETONIDE;

BONE EROSION; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG SAFETY; EXERCISE; HUMAN; JOINT SWELLING; LOW DRUG DOSE; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS;

EID: 82155192315     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.11.56     Document Type: Review

References (29)

1. Möttönen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353, 1568-1573 (1999).
2. Makinen H, Kautiainen H, Hannonen P et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J. Rheumatol. 34(2), 316-321 (2007).
3. Leirisalo-Repo M, Kautiainen H, Laasonen L et al. A randomized, double-blind, placebo-controlled study on addition of infliximab to the FIN-RACo DMARD combination therapy for initial six months in patients with early active rheumatoid arthritis. The NEO-RACo study. Presented at: EULAR 2008. Paris, France, 11-14 June 2008.
4. van Tuyl LH, Lems WF, Voskuyl AE et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann. Rheum. Dis. 67(11), 1574-1577 (2008).
5. Hetland ML, Stengaard-Pedersen K, Junker P et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann. Rheum. Dis. 67(6), 815-822 (2008).
6. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263-269 (2004).
7. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005).
8. Verstappen SM, Jacobs JWG, van der Veen MJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).Ann. Rheum. Dis. 66(11), 1443-1449 (2007).
9. Sokka T, Hetland ML, Makinen H et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 58(9), 2642-2651 (2008).
10. Khan N, Sokka T. American College of Rheumatology/European League Aganist Rheumatism Remission Criteria Achievement in Rheumatoid Arthritis: data from 32 countries. Rheumatoid arthritis clinical aspects: diagnostic and remission criteria. Presented at: 2011 ACR/ARHP Annual Scientific Meeting. Chicago, IL, USA, 4-9 November 2011.
11. Sokka T, Kautiainen H, Pincus T et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann. Rheum. Dis. 68(11), 1666-1672 (2009).
12. Kiely P, Walsh D, Williams R, Young A. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity - the early RA network (ERAN).Rheumatology (Oxford) 50(5), 926-931 (2011).
13. Sokka T, Pincus T. Quantitative joint assessment in rheumatoid arthritis. Clin. Exp. Rheumatol. 23, S58-S62 (2005).
14. Sokka T, Makinen H, Hannonen P, Pincus T. Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. Rheumatology (Oxford) 46(6), 1020-1023 (2007).
15. Luukkainen R, Kajander A, Isomäki H. Treatment of rheumatoid arthritis (letter).Br. Med. J. 2, 1501 (1978).
16. Wilske KR, Healey LA. Remodeling the pyramid - a concept whose time has come. J. Rheumatol. 16, 565-567 (1989).
17. Pincus T, Callahan LF. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - lessons from Hodgkin's disease and coronary artery disease. J. Rheumatol. 17, 1582-1585 (1990).
18. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the 'sawtooth' strategy. J. Rheumatol. 17(Suppl. 22), 12-15 (1990).
19. Pincus T. Rheumatoid arthritis: a medical emergency? Scand. J. Rheumatol. 23(Suppl. 100), 21-30 (1994).
20. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann. Rheum. Dis. 54, 944-947 (1995).
21. Weinblatt ME. Rheumatoid arthritis: treat now, not later! Ann. Intern. Med. 124, 773-774 (1996).
22. Makinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomized clinical trials for the rate of remission. Clin. Exp. Rheumatol. 24(Suppl. 43), S22-S28 (2006).
23. Sokka T, Envalds M, Pincus T. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod. Rheumatol. 18, 228-239 (2008).
24. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69(4), 631-637 (2010).
25. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59(6), 762-784 (2008).
26. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010).
27. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69(9), 1580-1588 (2010).
28. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann. Rheum. Dis. 64(10), 1410-1413 (2005).
29. Pincus T, Yazici Y, Bergman MJ. Hotel-based medicine. J. Rheumatol. 35(8), 1487-1488 (2008).